Cite
HARVARD Citation
Vose, J. et al. (n.d.). The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study. Leukemia & lymphoma. 54 (4), pp. 708-713. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Vose, J. et al. (n.d.). The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study. Leukemia & lymphoma. 54 (4), pp. 708-713. [Online].